PDCD1 and neoplasm: In addition, the tumor weights measured at endpoint (week 4) were significantly lower in the anti-PD1 + L-DOS47 group when compared to the control (p = 0.01), L-DOS47 (p = 0.01), and anti-PD1 (p = 0.03) monotherapy groups (Figure 4e,f; Table 2).